IQVIA Named a Leader in Medical Affairs and Regulatory Operations by Everest Group
11 Juillet 2024 - 2:30PM
Business Wire
IQVIA™ (NYSE:IQV) today announces that a leading, independent
research firm, Everest Group, has recognized IQVIA as a Leader in
its Life Sciences Regulatory and Medical Affairs Operations PEAK
Matrix® Assessment 2024 survey, which measures both market impact
and delivery effectiveness.
The Everest Group report highlights IQVIA’s focus on innovation
and its comprehensive portfolio of solutions that accelerates drug
development from molecule to market. IQVIA partners with customers
to plan, generate and disseminate trustworthy clinical and medical
evidence which drives the right stakeholder dialogue throughout the
asset lifecycle to advance regulatory and healthcare decision
making that improves patient outcomes.
A strong global footprint, along with AI-enabled technology and
analytic solutions allow IQVIA to ease the burden of regulatory
complexities and compliance demands in different geographies for
regulatory customers. IQVIA’s end-to-end solutions enable medical
affairs customers to manage and curate the richness of data coming
into their organization, transforming evidence into insights that
can enable actionable change. As with all IQVIA AI-powered
solutions, the AI capabilities in IQVIA’s medical affairs and
regulatory solutions are grounded in IQVIA Healthcare-grade AI™ –
AI engineered to meet the level of precision, speed and trust
required for life sciences and healthcare.
“IQVIA is honored to be recognized for its role in enabling our
medical affairs and regulatory customers to close the gap between
medical knowledge and medical practice to improve patients’ lives,”
said Rob Kotchie, president, Real World Solutions, IQVIA.
"IQVIA stands out as a prominent service provider distinguished
by its wide scope of services and extensive domain expertise, which
is further augmented through its collaborations with multiple
health authorities,” says Lloyd Fernandes, practice director,
Everest Group. “Furthermore, IQVIA is well-poised to cater to
enterprises' digitization needs via its suite of technology
solutions, including IQVIA RIM Smart, productivity tools for
electronic submissions, and IQVIA labeling solutions, enabling
enhanced process efficiencies."
To review the report, including details on IQVIA’s Leader
status, please click here.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources, extensive domain
expertise and network of partners. IQVIA Connected Intelligence™
delivers actionable insights and powerful solutions with speed and
agility — enabling customers to accelerate the clinical development
and commercialization of innovative medical treatments that improve
healthcare outcomes for patients. With approximately 87,000
employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240711696669/en/
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)
+1.919.780.3221
IQVIA (NYSE:IQV)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
IQVIA (NYSE:IQV)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024